IONS

NASDAQ · Biotechnology

Ionis Pharmaceuticals Inc

Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$75.71

-0.31 (-0.41%)

As of May 9, 1:07 AM ET ·

IONS News1 articles

Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline

Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.